Gsk (GSK) Net Income towards Common Stockholders (QoQ) (2009 - 2026)

Gsk (GSK) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 176.81%
Dec 31, 2025 -68.85%
Sep 30, 2025 41.10%
Jun 30, 2025 -5.89%
Mar 31, 2025 -28.18%
Dec 31, 2024 3,879.34%
Sep 30, 2024 -105.09%
Jun 30, 2024 11.58%
Mar 31, 2024 -65.67%
Dec 31, 2023 108.42%
Sep 30, 2023 -8.75%
Jun 30, 2023 12.21%
Mar 31, 2023 -89.68%
Dec 31, 2022 37.55%
Sep 30, 2022 1,108.47%
Jun 30, 2022 -56.36%
Mar 31, 2022 139.49%
Dec 31, 2021 -37.30%
Sep 30, 2021 -17.42%
Jun 30, 2021 31.78%